- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Biopsy, Biospecimen Collection, Computed Tomography, Golimumab, Magnetic Resonance Imaging, PSMA PET Scan, Bone Scan
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2449–2472
of 3,920
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- doxercalciferol, conventional surgery
- Dietary Supplement · Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 21 Years to 120 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Rochester, New York • Madison, Wisconsin + 1 more
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Interventions
- Xaluritamig, Darolutamide, Abiraterone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- San Francisco, California • Boston, Massachusetts • Minneapolis, Minnesota + 5 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- enzalutamide
- Drug
- Lead sponsor
- Alessa Therapeutics Inc.
- Industry
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Fresno, California • San Francisco, California • Chicago, Illinois + 7 more
- Conditions
- Prostate Cancer, Radiation Toxicity, Urinary Complication
- Interventions
- Lisinopril Tablets
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Prostate Cancer
- Interventions
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium, Flutamide, Ketoconazole, Nilutamide, Therapeutic Hydrocortisone, Vinblastine, Conventional Surgery
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Lead-in Enzalutamide followed by Placebo/Enzalutamide, Darolutamide during Lead-in Period, Lead-in Darolutamide followed by Radium-223/Darolutamide, Lead-in Darolutamide followed by Placebo/Darolutamide
- Drug
- Lead sponsor
- MANA RBM
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Myrtle Beach, South Carolina
- Conditions
- Prostatic Neoplasms
- Interventions
- TroVax, GM-CSF
- Biological · Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- tasquinimod, tasquinimod 0.25 mg; 0.5 mg, tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
- Drug
- Lead sponsor
- Andrew J. Armstrong, MD
- Other
- Eligibility
- 18 Years to 79 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Durham, North Carolina
- Conditions
- Prostate Cancer, Prostate, Prostate Adenocarcinoma
- Interventions
- 68Gallium-PSMA-11, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Interventions
- Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neoplasms, Cancer, Caregiver
- Interventions
- Not listed
- Lead sponsor
- Cancer Support Community, Research and Training Institute, Philadelphia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2035
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- GBM, Glioblastoma Multiforme, Gliosarcoma
- Interventions
- PSMA ADC
- Drug
- Lead sponsor
- Heinrich Elinzano, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island • Dallas, Texas
- Conditions
- Bone Metastases, Castration-Resistant Prostate Cancer
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 6
- States / cities
- San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, LHRH Agonist
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA
- Interventions
- OGX-427, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Costantine Albany
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 10
- States / cities
- Marina del Rey, California • Bloomington, Indiana • Goshen, Indiana + 6 more
- Conditions
- Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- cabazitaxel, prednisone, octreotide pamoate, questionnaire administration, octreotide acetate
- Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Ursolic Acid, Curcumin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cancer, Fatigue, Prostate Cancer, Breast Cancer, Cancer Survivor
- Interventions
- Not listed
- Lead sponsor
- National Institute of Nursing Research (NINR)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer (Diagnosis)
- Interventions
- Not listed
- Lead sponsor
- Xiangya Hospital of Central South University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- MUC-2-Globo H-KLH conjugate vaccine, QS21
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Enzalutamide, Abiraterone acetate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 5,506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Carcinoma
- Interventions
- Health Education, Informational Intervention, Survey Administration
- Behavioral · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona